Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma


This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.
Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma

Md Khadem Ali¹,², Richard Y. Kim²,³, Alexandra C. Brown², Jemma R. Mayall², Rafia Karim², James W. Pinkerton²,⁴, Gang Liu²,³, Kristy L. Martin⁵, Malcolm R. Starkey²,⁶, Amber Pillar², Chantal Donovan²,³, Prabuddha S. Pathinayake⁷, Olivia R. Carroll², Debbie Trinder⁸, Hock L. Tay², Yusef E. Badi⁹, Nazanin Z. Kermani¹⁰, Yi-Ke Guo¹⁰, Ritambhara Aryal⁵, Sharon Mumby⁹, Stelios Pavlidis⁹, Ian M. Adcock⁹, Jessica Weaver², Dikaia Xenaki¹¹, Brian G. Oliver¹¹, Elizabeth G. Holliday¹², Paul S. Foster², Peter A. Wark²,¹³, Daniel M. Johnstone¹⁴, Elizabeth A. Milward⁵, Philip M. Hansbro²,³,# and Jay C. Horvat²#

Affiliations: ¹Division of Pulmonary and Critical Care Medicine, Stanford University, California, United States of America. ²Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia. ³Centre for Inflammation, Centenary Institute, and Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia. ⁴Respiratory Pharmacology & Toxicology Group, National Heart & Lung Institute, Imperial College London, London, United Kingdom. ⁵School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle, New South Wales, Australia. ⁶Department of Immunology and Pathology, Central Clinical School, Monash
University, Melbourne, Victoria, Australia. 7Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. 8Medical School, Harry Perkins Medical Research Institute, University of Western Australia, Fiona Stanley Hospital, Perth, Western Australia, Australia. 9Airway Disease Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom. 10Data science institute, Department of computing, Imperial College London. 11Woolcock Institute of Medical Research, University of Sydney and School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia. 12Hunter Medical Research Institute, New Lambton, New South Wales, Australia and School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia. 13Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia. 14Discipline of Physiology and Bosch Institute, University of Sydney, Sydney, New South Wales, Australia.

*Authors contributed equally

**Correspondence to:** Associate Professor Jay Horvat, PhD, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, Callaghan, New South Wales, 2308, Australia, Tel: +61 2 4042 0220, F: +61 2 4042 0024, Email: jay.horvat@newcastle.edu.au

**Take home message**

The relationship between iron and the pathogenesis of asthma remains unclear. Here we show for the first time that altered iron responses are a key feature of clinical and experimental asthma and may play important roles in disease.
This article has supplementary material available from erj.ersjournals.com

Support statement: J.C.H. is supported by grants and fellowships from Cystic Fibrosis Australia and the Australian Cystic Fibrosis Research Trust and The University of Newcastle, Australia. P.M.H and D.T. are funded by Fellowships from the NHMRC (1079187 and 1020437). P.M.H. is also funded by an Investigator grant from the NHMRC of Australia (1175134).

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Short Running Head: Iron and the pathogenesis and severity of asthma
ABSTRACT

Accumulating evidence highlights links between iron regulation and respiratory disease. Here, we assessed the relationship between iron levels and regulatory responses in clinical and experimental asthma.

We show that cell-free iron levels are reduced in the bronchoalveolar lavage (BAL) supernatant of severe or mild-moderate asthma patients and correlate with lower forced expiratory volume in one second (FEV1). Conversely, iron-loaded cell numbers were increased in BAL in these patients and with lower FEV1/forced vital capacity (FEV1/FVC). The airway tissue expression of the iron sequestration molecules divalent metal transporter 1 (DMT1) and transferrin receptor 1 (TFR1) are increased in asthma with TFR1 expression correlating with reduced lung function and increased type 2 (T2) inflammatory responses in the airways. Furthermore, pulmonary iron levels are increased in a house dust mite (HDM)-induced model of experimental asthma in association with augmented Tfr1 expression in airway tissue, similar to human disease. We show that macrophages are the predominant source of increased Tfr1 and Tfr1+ macrophages have increased IL13 expression. We also show that increased iron levels induce increased pro-inflammatory cytokine and/or extracellular matrix (ECM) responses in human airway smooth muscle (ASM) cells and fibroblasts ex vivo and induce key features of asthma, including airway hyper-responsiveness and fibrosis and T2 inflammatory responses, in vivo.

Together these complementary clinical and experimental data highlight the importance of altered pulmonary iron levels and regulation in asthma, and the need for a greater focus on the role and potential therapeutic targeting of iron in the pathogenesis and severity of disease.
Introduction

Clinical and experimental evidence suggests that altered levels of systemic and lung iron and/or iron regulatory molecules are associated with lung inflammation in many diseases including asthma (1). Chronic inflammatory responses that underpin many respiratory diseases are associated with decreased systemic iron levels (2, 3). There is a correlation between low maternal iron status during pregnancy with childhood wheezing, impaired lung function and atopic sensitisation (4), and low foetal iron is linked with increased susceptibility to eosinophilia in infancy (5). In a longitudinal study of parents and children, higher umbilical cord iron status was associated with decreased occurrence of wheezing and eczema, while lower iron status is linked to increased risk of atopy (6). Furthermore, lower serum and exhaled breath condensate iron levels are associated with asthma in children and adults (7-9). However, plasma iron and malondialdehyde levels, a marker of oxidative stress are significantly elevated in asthmatic subjects compared to healthy controls (10, 11). Ferritin levels are increased in the lungs in an experimental mouse model of asthma (12). Ferritin and iron levels were reduced by intranasal administration of iron chelator complexes in this model, with treatment also attenuating inflammation (12). By contrast, short-term intraperitoneal injection of iron dextran suppresses hallmark features of asthma in an acute mouse model (13), suggesting that increasing systemic iron levels may protect against disease. However, the potential pathological effects of chronically increasing systemic iron levels, and the effects on iron accumulation in the lung in asthma remain unexplored. Together, these findings provide evidence that asthma is associated with altered iron homeostasis. However, it is unclear whether altered iron levels play roles in pathogenesis or are a consequence of disease. Further clinical and experimental studies investigating the link between iron and asthma are required to better understand the mechanisms involved and address whether increased or decreased pulmonary iron levels are detrimental. In order to
address this, we assessed the levels of iron and iron-related gene expression in the airways of patients with severe or mild-moderate asthma and healthy controls. We show that altered iron metabolism in the airways is associated with asthma. Specifically, reduced extracellular iron levels, and increased cellular iron accumulation and airway TFR1 expression are linked with disease severity, suggesting that iron sequestration/accumulation in cells/tissues may play roles in asthma pathogenesis. We also show that experimental asthma is associated with increased airway Tfr1 expression that corresponds with increased pulmonary iron accumulation. These findings led us to hypothesise that increased iron accumulation in the lung plays a key role in driving the key features of asthma. We confirmed this by showing that increased lung iron levels in two murine models of iron overload result in the development of key asthma features similar to that observed in HDM-induced experimental disease.

**Methods**

Full details are provided in online supplementary material.

**Study approvals**

All experiments were conducted with approval of the Human/Animal Ethics Committees of the University of Newcastle, Australia and the local ethics committees of the Unbiased Biomarkers in Prediction of respiratory disease outcomes (U-BIOPRED) clinical centres.

**Clinical analyses**

Levels of iron were assessed in bronchoalveolar lavage (BAL) cells from 11 severe and 12 mild-moderate, asthma patients and 13 healthy controls using Perl’s-DAB. In the same
cohorts, iron regulatory factors were assessed in airway biopsy tissues using qPCR. Colorimetric non-haem iron assay was used to measure non-haem iron content in BAL supernatants collected from a second set of severe and mild-moderate asthma patients and healthy controls (n=10 subjects/group). In both sets of donors, asthma severity was categorised based on FEV1% predicted and asthma severity symptoms/day/night (Tables 1 and 2). The transcriptomic profile of iron regulatory factors was analysed in bronchial brushings of 39 severe and 29 mild-moderate asthmatics and 40 healthy controls within the U-BIOPRED cohort (14).

**Iron overloaded mice; experimental asthma model; iron quantification; airway inflammation; small airway fibrosis; lung function, flow cytometry analyses of different cell populations in murine lung tissue, human primary ASM and lung fibroblast cell culture, primary bronchial airway epithelial cells (pBECs) cultured at the air-liquid interface (ALI)**

Haemochromatosis protein gene (Hfe)-deficient (Hfe<sup>−/−</sup>) and wild-type (WT) mice on an AKR background (36 weeks old) (15), and WT BALB/c mice (8 week-old) fed a high iron diet (supplemented with 2% carbonyl iron, HID) for 8 weeks, were used to model iron overload. House dust mite (HDM)-induced experimental asthma was induced in Hfe<sup>−/−</sup> and WT BALB/c mice fed HID, normal (control chow, CC) or low iron diets (LID) (Figure E1). Iron quantification, airway inflammation, small airway fibrosis, lung function, pulmonary cell population characterisations, cytokines and ECM responses in human primary ASM cells and lung fibroblasts and iron related gene expression in pBECs were assessed as previously described (16-34) and as outlined in the online supplement.
Statistics

Comparisons between two groups were performed using a non-parametric Mann-Whitney test. Comparisons between multiple groups were performed using Kruskal-Wallis one-way analysis of variance (ANOVA) with uncorrected Dunn’s post-hoc test. AHR data were analysed using two-way repeated measures ANOVA with Bonferroni post-hoc test. Correlation analyses were performed using Spearman rank correlation.

Results

Iron levels in BAL supernatant are reduced, but iron-positive cell numbers in BAL are increased, in asthma

We first assessed cell-free non-haem iron levels and iron-loaded cell numbers in BAL obtained from severe or mild-moderate asthma patients and healthy controls. Iron levels in BAL supernatant were reduced in combined severe and mild-moderate asthma patients compared to healthy controls, with the greatest decrease in severe disease (Figure 1A and B). Non-haem iron levels positively correlate with FEV1% predicted but not FEV1/FVC (Figure 1C and D). Non-haem iron levels negatively correlate with inhaled corticosteroid (ICS) used in asthmatics (Figure 1E). In contrast, severe and mild-moderate asthma patients have increased numbers of iron-positive cells in BAL compared to healthy controls (Figure 1F-H). Iron-positive BAL cell numbers negatively correlate with FEV1/FVC but not FEV1% predicted (Figure 1I and J). Together these novel findings show that decreased extracellular iron levels in the airway lumen, but increased iron in BAL cells, correlate with declines in lung function in asthma, suggesting a relationship between cellular sequestration/accumulation of iron and impaired lung function.
Key iron sequestration molecules divalent metal transporter 1 ($DMT1$) and transferrin receptor 1 ($TFR1$) levels are increased in the airways of asthma patients

We next assessed whether iron sequestration molecules $DMT1$ and $TFR1$ levels are increased in the airways of asthmatics. $DMT1$ and $TFR1$ mRNA expression are increased in the airways of asthma patients compared to healthy controls (Figure 2A and D). $DMT1$ and $TFR1$ expression negatively correlates with FEV1/FVC with similar correlations observed for FEV1% predicted (Figure 2B, C, E and F). We confirm that $TFR1$ expression is increased in airways brushings from a separate cohort of asthma patients (Figure 2G). Importantly, TFR1 expression is strongly and positively associated with group 2 innate lymphoid cells ($ILC2$) (35), interleukin 4 ($IL4$), $IL5$ and $IL13$ expression (Figure 2H-K). Collectively, these data provide evidence that increased iron sequestration into airway tissues and/or cells due to increased $DMT1$ and $TFR1$ expression may play crucial roles in the pathogenesis and severity of asthma.

Expression of iron uptake, transport, storage, and regulatory factors is altered in the airways and pBECs of asthma patients

We next assessed whether the expression of other iron related genes is altered in the airways of asthma patients. Severe asthma patients have increased iron uptake molecules, transferrin receptor 2 ($TFR2$), zinc transporter (ZIP14), natural resistance-associated macrophage protein 1 ($NRAMP1$) ($p=0.08$) and iron storage molecules ferritin heavy chain ($FTH$) ($p=0.06$) expression compared to healthy controls (Figure 3A-D). The levels of $NRAMP1$, $FTH$, ferritin light chain ($FTL$) and iron regulatory protein 1 ($IRP1$) expression is significantly
higher in the airways of mild asthma patients compared to healthy controls (Figure 3C-F). Hepcidin (HAMP) expression is decreased in severe asthma airways compared to healthy controls \((p=0.06)\) (Figure 3G). Interestingly, FTL is lower in severe compared to mild asthma patients (Figure 3E). There is no significant change in iron exporter ferroportin (FPN) expression in any of the groups (Figure 3H). Together these data show that factors associated with increased intracellular iron uptake and storage are largely increased in the airways of asthma patients, which may explain the decreases in extracellular iron levels in BAL supernatant and increased iron accumulation in cells/tissues.

To explore which cells are associated with altered iron in the airways, we next assessed expression of DMT1, TFR1, TFR2, ZIP14, NRAMP1, FTH, FTL, IRP1, FPN in pBECs obtained from asthmatic patients and healthy controls cultured at the ALI. Like with mRNA expression changes observed in airway tissue biopsy and bronchial brushings, we show that TFR1 and TFR2 expression is significantly increased in the pBECs of asthmatics (Figure 3J and K). There is no significant change in expression of any other factors (Figure 3I, L-Q).

Iron levels and Tfr1\(^+\) macrophages are increased in the lungs in HDM-induced experimental asthma, and increased iron induces pathological responses in ASM cells and lung fibroblasts

We next determined whether the levels of iron and regulatory factors are similarly altered in HDM-induced experimental asthma (Figure E2) and whether exogenous iron alters cytokines and ECM responses in primary human ASM cells and lung fibroblasts. We show that HDM-induced experimental asthma is also associated with the accumulation of non-haem iron in lung tissue (Figure 4A), with iron accumulation mostly in macrophages around the airways (Figure 4B). We find increased numbers of iron-positive cells in BAL (Figure 4C) and
increased expression of \textit{Tfr1} in the airways (\textbf{Figure 4D}) and transferrin levels in BAL supernatant (\textbf{Figure 4E}). Together, our clinical and experimental data provide evidence for increased iron accumulation in lung tissues and cells in asthma that are either playing a role in, and/or are a consequence of, the pathogenesis of asthma. We next assessed the cellular source of increased \textit{Tfr1} using flow cytometry. We show that the number of \textit{Tfr1}+ cells are increased in HDM-challenged mice and that these cells are predominantly alveolar and interstitial macrophages (\textbf{Figure 4F}). These data suggest that HDM-induced experimental asthma is characterised by an increase in macrophages that sequester iron. To determine whether these \textit{Tfr1}+ macrophage populations have a different phenotype, we measured expression of \textit{Il10}, \textit{Tgf\b}, \textit{Ifng} and \textit{Il13} in \textit{Tfr1}+ and \textit{Tfr1}− macrophages in HDM-induced experimental asthma and saline-challenged controls (\textbf{Figure 4G-J}). We show that \textit{Tfr1}+ macrophages from HDM-challenged mice have increased \textit{Il10} and \textit{Il13} expression compared to those from saline-challenged controls as well \textit{Tfr1}− macrophages from both saline- or HDM-challenged groups (\textbf{Figure 4G and J}). This suggests that iron-sequestering, \textit{Tfr1}+ macrophages may play a pathologic role in asthma by promoting T2 inflammatory responses.

To further characterise the potential effects of increased extracellular iron levels in tissues, we also exposed human ASM cells and fibroblasts to increasing concentrations of ferric ammonium citrate (FAC). Increasing concentrations of FAC increase pro-inflammatory cytokine (IL-6 and IL-8) production and/or ECM gene (\textit{TNC}) expression by these cells (\textbf{Figure 4K-P}).

\textbf{Hfe}−/− iron overload mice have increased iron levels in the lung associated with increased features of asthma

We next assessed the consequences of increased iron accumulation in lung tissues and cells on the pathogenesis and severity of key features of asthma using murine models of iron
overload. In the absence of HDM treatment, sham (PBS)-treated $Hfe^{+/-}$ mice, which overload iron systemically (e.g. in liver, **Figure 5A**), have significantly higher lung iron levels compared to sham-treated, WT controls (**Figure 5B**). Whilst HDM increases iron levels in the lungs of WT mice compared to sham-treated WT controls, it does not further enhance levels in $Hfe^{+/-}$ mice (**Figure 5B**). Increased iron in all groups is predominantly deposited in macrophages surrounding the airways and in the alveoli (**Figure 5C**).

We also demonstrate that increased iron accumulation observed in sham-treated $Hfe^{+/-}$ mice is associated with increases in leukocyte numbers in BAL and lung interleukin 13 ($Il13$) expression, which lead to small airway fibrosis and AHR compared to sham-treated WT controls (**Figure 5D, E, J-M**). Indeed, these features were similar to those observed in HDM-treated WT controls. HDM treatment in $Hfe^{+/-}$ mice increased the severity of all of the disease features compared to HDM-treated, WT controls (**Figure 5D, E, J-M**). Together, these data demonstrate that pulmonary iron accumulation alone can drive key features of asthma, and that a combination of iron overload and HDM treatment may contribute to more severe features of experimental asthma.

**Diet-induced iron accumulation also increases key features of asthma**

To confirm our findings with $Hfe^{+/-}$ mice, we next assessed the effects of HID-induced iron overload on disease features. Similar to our findings in $Hfe^{+/-}$ mice, WT mice fed a HID, which overload iron systemically (**Figure 6A**), have increased pulmonary iron levels compared to mice fed CC (**Figure 6B**). Furthermore, like findings in $Hfe^{+/-}$ mice, diet-induced iron overload increases lung iron levels following HDM treatment with similar levels observed in HDM-treated mice on HID and CC diets (**Figure 6B**). Consistent with findings in $Hfe^{+/-}$ mice, iron accumulation in the lungs of HID fed mice is associated with airway fibrosis and AHR in the absence of HDM treatment (**Figure 6H-K**). HID-induced increases
the severity of HDM-induced experimental asthma, with small airways fibrosis and AHR increased in HID compared to CC fed HDM-treated mice (Figure 6H-K). There were some discrepancies observed between the effects *Hfe<sup>−/−</sup>* mice compared to HID fed mice. HID-fed mice did not exhibit increases in BAL leukocyte numbers, but did have elevated tissue eosinophil numbers in HDM-induced experimental asthma (Figures 6C-E). These data confirm that increased iron accumulation in the lung can drive the pathogenesis and increase the severity of key asthma features.

Interestingly, mice fed a LID, despite having reduced liver iron levels (Figure 6A), do not have reduced lung iron levels in the absence of HDM treatment (Figure 6B). However, LID fed mice do have reduced lung iron accumulation in HDM-induced experimental asthma (Figure 6B), which is associated with decreases in total leukocyte numbers in BAL and MSC numbers around the airways (Figure 6C, F and G). The decrease in lung iron levels has no effect on HDM-induced airway fibrosis or AHR (Figure 6H-K).

Together, these data show that the relationships between lung iron levels and the pathogenesis and severity of asthma is complex. Nevertheless, these data provide new evidence that increased iron accumulation in the lung plays key roles in driving the characteristic features of asthma.

**Discussion**

Clinically, both low (7, 8) and high (10, 11, 36) systemic iron has been reported in asthma. In most clinical studies, iron levels are assessed systemically in serum/plasma but not locally in the lung with only one study showing that low iron in exhaled breath condensate is associated with asthma (9). However, it is unclear whether altered iron levels play a role in pathogenesis, or if they are a consequence, of disease. To investigate the potential role of iron
level and/or regulation in the lung in the pathogenesis and severity of asthma, we first assessed iron levels in the BAL supernatant and cells of patients with mild-moderate and severe asthma compared to healthy controls. We show, for the first time, that non-haem iron levels in BAL supernatant are markedly lower in asthma patients compared with healthy controls. Significantly, when the asthma patients are separated into mild-moderate and severe groups, non-haem iron levels are further significantly reduced in patients with severe asthma. In contrast to the decreased iron levels in BAL supernatant, we show that the number of iron-loaded cells are increased in the BAL of patients with mild-moderate and severe asthma. Both the levels of extracellular iron in supernatant and iron-loaded cell numbers in BAL correlate with lung function, with higher extracellular iron levels associated with better, and higher iron-positive cells associated with worse, lung function. This is the first report showing correlations between airway iron homeostasis and key lung function parameters. Taken together, our data suggest that lower extracellular, and higher intracellular, iron in the airways is associated with asthma and is linked with disease severity.

Our clinical data, suggesting that asthma is associated with increased iron sequestration/accumulation into cells and/or tissues, is supported by our findings that DMT1 and/or TFR1 expression is significantly increased in the airways in clinical and experimental asthma and correlate with impairment of lung function. In the lung, iron is mostly imported into cells by TFR1 as well as DMT1 and natural resistance-associated macrophage protein 1 (NRAMP1) (1, 37-39). Thus, increased expression of DMT1 and TFR1 may contribute to the decreased extracellular, and increased intracellular, iron that we observe in BAL of asthma patients. These changes may be a consequence of chronic inflammatory responses that underpin disease. Inflammation is a well-known promoter of iron sequestration into cells, predominantly due to cytokine-mediated modification of hepcidin responses (40). A previous study showed that liver specific Hepe−/− mice had increased iron in the lung similar to Hepc
globally deficient mice, suggesting that systemic hepcidin plays a predominant role in regulating iron levels in the lung (41). However, studies are still required to determine whether hepcidin regulation occurs at a subtle level locally within the lung. IL-6 also enhances TFR1 responses and iron uptake in hepatocytes (42). TFR expression is upregulated in the lungs of rats exposed to lipopolysaccharide (43). We extend these findings by showing that TFR1 expression is associated with increased T2 inflammatory gene (\textit{IL4}, \textit{IL5} and \textit{IL13}) expression the in asthmatic airways. We also show that Tfr1+ macrophages are increased in the lungs during HDM-induced experimental asthma and that these cells display a phenotype of increased \textit{Il13} expression. We also show that exogenous iron increases pro-inflammatory cytokine and ECM responses in human ASM cells and/or lung fibroblasts. Together these data suggest that increased extracellular iron levels in lung tissue may drive disease through increasing pathological responses ASM cells and fibroblasts. Our data suggest that increased iron sequestration by Tfr1+ macrophages, perhaps as a protective response to increased extracellular iron levels and/or innate pro-inflammatory responses in the asthmatic airway, may result in the induction of T2 inflammatory responses that play a key role in the pathogenesis of asthma.

Whilst our initial findings suggest strong links between the sequestration/accumulation of iron into cells/tissues and the pathogenesis and severity of asthma, they do not show whether changes in iron homeostasis that result in increased iron accumulation in cells is a driver or consequence of disease. To investigate the roles of pulmonary iron accumulation in disease, we employed a complementary suite of murine models of iron overload and chronic HDM-induced experimental asthma. We show that both genetic (\textit{Hfe}−/− mice) and dietary (mice fed a HID) models of iron overload result in significant accumulation of iron in lung tissues. This iron accumulation is similar to that observed in HDM-induced experimental asthma. Furthermore, iron overload-induced
pulmonary iron accumulation results in the presentation of many of the key features of asthma, including airways inflammation, type 2 cytokine (IL-13) production, airway fibrosis and AHR. Together, these data provide strong evidence that increased tissue iron levels play a key functional role in the pathogenesis and increased severity of asthma.

To conclude, complementary clinical and experimental studies show a strong relationship between iron level and regulation and the pathogenesis and severity of asthma. We show, for the first time, that altered levels of iron and iron-related gene expression in the airways of patients with asthma is linked with lung function with evidence for increased iron accumulation into tissues being detrimental for disease. Using murine models, we show that increased lung iron accumulation drives the pathogenesis and severity of key features of asthma. Due to the small amounts of tissue available or lack of available RNA we were not able to measure iron levels in airway tissue biopsies, or iron regulatory gene expression in BAL cells. We also used bronchoscopy samples from two different cohorts. These are limitations of the current study. Nevertheless, our findings highlight the need for further studies to investigate the mechanisms that underpin the effects of iron dysregulation on the pathogenesis and severity of asthma and to explore and test novel iron-targeted therapies. Given the interactions that occur between microbes and iron and the role of infection in asthma, further studies are also required to explore the inter-relationship between microbiomes, iron levels/regulation, mucosal immunity and asthma.

Acknowledgements

Supported by grants and fellowships from Cystic Fibrosis Australia and the Australian Cystic Fibrosis Research Trust and The University of Newcastle, Australia. P.M.H and D.T. are
funded by Fellowships from the NHMRC (1079187 and 1020437). P.M.H. is also funded by an Investigator grant from the NHMRC of Australia (1175134).

References


Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. *Am J Respir Crit Care Med* 2017; 195: 443-455.


Argraves WS, Oliver BG, Knight DA, Burgess JK, Hansbro PM. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c. *J Pathol* 2017; 243: 510-523.


33. Hsu AC, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, Barr I, Mahony JB, Foster PS, Knight DA, Wark PA, Hansbro PM. Targeting PI3K-p110alpha


**Figure legends**

**Figure 1. Iron regulation in the airways is altered in asthma.** Non-haem iron (NHI) levels were measured in bronchoalveolar lavage (BAL) supernatant collected from patients with severe or mild-moderate asthma and healthy controls (n=10/group) (A, B). Non-haem iron levels were correlated with FEV1% predicted and FEV1/FVC (C, D). Non-haem iron levels were negatively correlated with inhaled corticosteroid (ICS) use (E). BAL cells were stained with Perl’s-DAB and iron-positive cells enumerated (n=8-10) (F-H). Correlations between iron-positive cells and FEV1% predicted, and FEV1/FVC (I, J). Correlations for each comparison are represented as Spearman rank correlation coefficient (Spearman rho; r). Data are presented as means ± SEM. *p<0.05, **p<0.01 compared to respective controls.

**Figure 2. Increased DMT1 and TFRII expression in the airways correlates with impaired lung function in asthma patients.** DMT1 and TFRII mRNA expression was quantified in the airway tissues collected from 7 severe and 7 mild-moderate asthmatic patients, and 6 healthy controls using qPCR (A, D). Relative expression to the reference gene beta (β)-actin was performed. DMT1 and TFRII expression levels negatively correlate with FEV1% predicted and FEV1/FVC (B, C and E, F). Correlations for each comparison are represented as
Spearman rank correlation coefficient (Spearman rho; $r$). TFR1 mRNA expression in the bronchial brushings of asthma patients within U-BIOPRED cohort (G). TFR1 expression was positively correlated with $ILC2$, $IL4$, $IL5$ and $IL13$ expression (H-K). Data are presented as means ± SEM. *$p<0.05$, **$p<0.01$ compared to respective controls.

**Figure 3. Altered expressions of iron regulatory factors in the airways of asthma patients.** The mRNA expression of TFR2 (A), ZIP14 (B), NRAMP1 (C), FTH (D), FTL (E), IRP1 (F), HAMP (G) and FPN (H) was assessed in the airway tissues collected from 7 severe and 7 mild-moderate asthma patients and 6 healthy controls using qPCR. The mRNA expression of DMT1 (I), TFR1(J), TFR2 (K), ZIP14 (L), NRAMP1 (M), FTH (N), FTL (O), IRP1 (P) and FPN (Q) was also assessed using qPCR in primary bronchial epithelial cells obtained from 7 severe asthmatic patients and 8 healthy controls that have been cultured at the air-liquid interface (ALI). Relative expression to the reference gene $\beta$-actin and GAPDH is presented. Relative expression to the reference gene $\beta$-actin is presented. Data are presented as means ± SEM. *$p<0.05$, **$p<0.01$ compared to respective controls.

**Figure 4. Iron levels are increased in the lung in house dust mite (HDM)-induced experimental asthma.** Six-8 week old wild-type (WT) BALB/c mice were intranasally administered HDM antigen for 5 days per week for 6 weeks and then major features of HDM-induced experimental asthma were assessed. Non-haem iron (NHI) content was measured in the lung homogenates (A). Localisation of iron in the lung was assessed in Perls’-DAB stained lung sections (B). Iron-positive cells were enumerated in Perls-stained BAL cells (C). Tfr1 expression was measured in the airways tissue using qPCR (D). Transferrin levels were measured by ELISA (E). Tfr1$^+$ cells were sorted using FACS analysis (F). Expression of Il10, Tgfb, Ifng and Il13 was assessed in sorted Tfr1$^+$ and Tfr1$^-$.
macrophages in the presence and absence of HDM-induced experimental asthma using qPCR (G-J). Levels of TNC and IL6 and IL8 were measured in FAC-treated ASM and lung fibroblast cells using qPCR and ELISA, respectively (K-P). Scale bar: 50 μm. Data are presented as mean ± SEM (n=6-8), pooled from two repeat experiments. **p<0.01; ***p<0.001; ****p<0.0001 compared to PBS controls.

**Figure 5. Absence of Hfe increases the severity of house dust mite (HDM)-induced experimental asthma.** HDM was administered to ~36 weeks old wild-type (WT) AKR and Hfe+/− mice for 5 days per week for 6 weeks and then the hallmark features of experimental asthma were assessed. (A) Levels of non-haem iron (NHI) were measured in the liver (A) and lung (B). Localisation of iron in the lung was assessed in Perls’-DAB stained lung sections (C). Total leukocytes were enumerated in processed BAL (D). Il13 mRNA expression was measured by qPCR (E). Tissue eosinophilic inflammation was quantified in chrome salt fixation-stained lung sections (F, G). Mucus secreting cells were enumerated around the airways in PAS-stained lung sections (H, I). Area of collagen deposition surrounding the basement membrane of small airways was determined in Sirius red-stained lung tissue sections, in 6-8 airways/mouse using ImageJ (J, K). Airways hyper-responsiveness (AHR), in terms of central airway resistance (Rn), was measured in response to increasing concentrations of nebulised methacholine (Mch) (L). Rn at 10mg/mL Mch was determined from AHR curves (M). Scale bar: 50 μm. Data are presented as mean ± SEM (n=6-10), pooled from two repeat experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

**Figure 6. High iron diet-induced iron accumulation increases the key features of asthma.** Wild-type (WT) BALB/c female mice (6-8 weeks old) were fed low iron (LID), normal control chow (CC) and high iron diets (HID) and were intranasally administered
house dust mite (HDM) antigen or PBS 5 days a week for up to 6 weeks. Non-haem iron (NHI) content was measured in the liver and lung by non-haem iron assay (A, B). Total leukocytes were enumerated in the processed BAL (C). Numbers of eosinophils were quantified around the most inflamed airways in chrome salt fixation-stained lung sections (D, E). Mucus secreting cells were enumerated around airways in PAS-stained lung sections (F, G). Area of collagen deposition surrounding the basement membrane of small airways was quantified in Sirius red-stained lung tissue sections, in 6-8 airways/mouse using ImageJ (H, I). Airways hyper-responsiveness (AHR) in terms of central airway resistance (Rn) was measured in response to inhaled increasing concentrations of methacholine (Mch) (J). Rn at 30mg/mL Mch was determined from AHR curves (K). Scale bar: 50 μm. Data are presented as mean ± SEM (n=6-19), pooled from 3 repeat experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 compared to respective controls.

**Table 1.** Human sample donor characteristics (Iron metabolism genes expression in airway biopsy tissues and iron scores in BAL cells)

**Table 2.** Human sample donor characteristics (Non-heme iron quantification in BAL)
Figure 2.
Figure 4.
Figure 5.
Figure 6.
Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Healthy</th>
<th>Mild-moderate asthmatics</th>
<th>Severe asthmatics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects, n</td>
<td>13</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>Age, yr</td>
<td>53.00 ± 4.729</td>
<td>55.92 ± 4.583</td>
<td>53.73 ± 3.681</td>
</tr>
<tr>
<td>Sex, M/F</td>
<td>4/9</td>
<td>6/6</td>
<td>2/9</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>-</td>
<td>31.22 ± 2.302</td>
<td>31.71 ± 4.313</td>
</tr>
<tr>
<td>FEV1% predicted</td>
<td>102.7 ± 4.494</td>
<td>86.92 ± 2.726**</td>
<td>76 ± 5.389***</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.817 ± 0.021</td>
<td>0.730 ± 0.016&quot;</td>
<td>0.656 ± 0.049&quot;</td>
</tr>
<tr>
<td>ACQ</td>
<td>-</td>
<td>0.903 ± 0.168</td>
<td>2.166 ± 0.291*</td>
</tr>
<tr>
<td>Total cells (x10⁹/mL BAL)</td>
<td>0.170 ± 0.026</td>
<td>0.129 ± 0.021</td>
<td>0.853 ± 0.327*</td>
</tr>
<tr>
<td>Macrophages (x10⁹/mL BAL)</td>
<td>0.053 ± 0.011</td>
<td>0.068 ± 0.021</td>
<td>0.128 ± 0.031*</td>
</tr>
<tr>
<td>Neutrophils (x10⁹/mL BAL)</td>
<td>0.065 ± 0.013</td>
<td>0.031 ± 0.010</td>
<td>0.653 ± 0.311</td>
</tr>
<tr>
<td>Eosinophils (x10⁹/mL BAL)</td>
<td>0.002 ± 0.000</td>
<td>0.039 ± 0.017</td>
<td>0.050 ± 0.019*</td>
</tr>
<tr>
<td>ICS, yes/no</td>
<td>NA</td>
<td>9/3</td>
<td>11/0</td>
</tr>
<tr>
<td>ICS dose⁴</td>
<td>NA</td>
<td>543.30 ± 126.70</td>
<td>800.00 ± 80.90</td>
</tr>
<tr>
<td>LABA, yes/no</td>
<td>NA</td>
<td>6/6</td>
<td>11/0</td>
</tr>
<tr>
<td>LAMA, yes/no</td>
<td>NA</td>
<td>4/8</td>
<td>5/6</td>
</tr>
<tr>
<td>SABA, yes/no</td>
<td>NA</td>
<td>5/7</td>
<td>5/6</td>
</tr>
<tr>
<td>OCS, yes/no</td>
<td>NA</td>
<td>0/12</td>
<td>2/9</td>
</tr>
</tbody>
</table>

M/F, male/female; BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ACQ, asthma control questionnaire; BAL, bronchoalveolar lavage; NA, not applicable; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; OCS, oral corticosteroids; yr, year. ⁴Equivalent to Fluticasone μg/day. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to healthy controls; *p<0.05, **p<0.01 compared to mild-moderate asthmatics.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Healthy</th>
<th>Mild-moderate asthmatics</th>
<th>Severe asthmatics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects, n</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Age, yr</td>
<td>58.56 ± 2.724</td>
<td>60.70 ± 5.327</td>
<td>56.00 ± 3.841</td>
</tr>
<tr>
<td>Sex, M/F</td>
<td>4/6</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>FEV1% predicted</td>
<td>97.5 ± 5.861</td>
<td>89.6 ± 4.759</td>
<td>66.33 ± 7.427**,*</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.812 ± 0.008</td>
<td>0.741 ± 0.023*</td>
<td>0.745 ± 0.035</td>
</tr>
<tr>
<td>ACQ</td>
<td>-</td>
<td>4.778 ± 0.8127</td>
<td>7.333 ± 3.18</td>
</tr>
<tr>
<td>Total cells (x10^6/mL BAL)</td>
<td>0.110 ± 0.028</td>
<td>0.138 ± 0.027</td>
<td>0.126 ± 0.016</td>
</tr>
<tr>
<td>Macrophages (x10^6/mL BAL)</td>
<td>0.037 ± 0.009</td>
<td>0.031 ± 0.008</td>
<td>0.051 ± 0.013</td>
</tr>
<tr>
<td>Neutrophils (x10^6/mL BAL)</td>
<td>0.025 ± 0.009</td>
<td>0.053 ± 0.022</td>
<td>0.039 ± 0.008</td>
</tr>
<tr>
<td>Eosinophils (x10^6/mL BAL)</td>
<td>0.000 ± 0.000</td>
<td>0.020 ± 0.011</td>
<td>0.029 ± 0.012</td>
</tr>
<tr>
<td>ICS, yes/no</td>
<td>NA</td>
<td>8/2</td>
<td>10/0</td>
</tr>
<tr>
<td>ICS dose$</td>
<td>NA</td>
<td>432.0 ± 110.4</td>
<td>1063 ± 174.2</td>
</tr>
<tr>
<td>LABA, yes/no</td>
<td>NA</td>
<td>5/5</td>
<td>10/0</td>
</tr>
<tr>
<td>LAMA, yes/no</td>
<td>NA</td>
<td>2/8</td>
<td>6/4</td>
</tr>
<tr>
<td>SABA, yes/no</td>
<td>NA</td>
<td>4/6</td>
<td>4/6</td>
</tr>
<tr>
<td>OCS, yes/no</td>
<td>NA</td>
<td>0/10</td>
<td>0/10</td>
</tr>
</tbody>
</table>

M/F, male/female; BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ACQ, asthma control questionnaire; BAL, bronchoalveolar lavage; NA, not applicable; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; OCS, oral corticosteroids; yr, year. $Equivalent to Fluticasone μg/day. Data are shown as mean ± SEM. *p<0.05, **p<0.01, compared to healthy controls; *p<0.05 compared to mild-moderate asthmatics.
Supplementary Methods

Study approvals

All experiments were conducted with approval of the Human/Animal Research Ethics Committees of the University of Newcastle, Australia and the Unbiased Biomarkers in Prediction of respiratory disease outcomes (U-BIOPRED) centre.

Human subjects

Airway biopsy tissues and bronchoalveolar lavage (BAL) were collected from 11 severe, 12 mild-moderate asthmatics and 13 healthy subjects. To measure non-haem iron content in BAL supernatant, BAL samples were also collected from a second set of severe or mild-moderate asthma patients and healthy subjects (10 subjects in each group). Subjects with severe or mild-moderate asthma had mean FEV1% predicted at 86.92 ± 2.726 (p<0.01) and 76 ± 5.389 (p<0.001), respectively, compared to healthy controls (102.7 ± 4.494, Table 1). BAL was collected from another set of 10 subjects in each group: severe (mean FEV1% predicted, 66.33 ± 7.427, p<0.01) or mild-moderate asthma (mean FEV1%, 89.6 ± 4.759) or healthy controls (mean FEV1%, 97.5 ± 5.861) (Table 2). Human bronchial airway epithelial cells (pBECs), airway smooth muscle (ASM) cells and lung fibroblasts donor characteristics are shown in Tables E5 and 6. Patient exclusion criteria included current smokers, recent exacerbation, respiratory tract infection in the last 4 weeks and age younger than 18yrs.

Human BAL

For each donor, BAL was collected by instilling sterile warm saline (2x 60mL) into the airways using elective fibreoptic bronchoscopy, as described previously (1). Collected BAL was
filtered through a nylon filter apparatus, centrifuged (400x g, 10 mins) and then supernatant was stored at −80°C for future analysis. BAL cell pellets were resuspended in PBS and cytopsins were prepared, stained with Diff-quik solutions for 30 sec, solution II (fixative) for 30 sec, solution I for 30 sec, dehydrated and air-dried overnight for cover slipping. Differential cells were analysed based on morphology as previously described (1).

**Quantification of iron-laden BAL cells**

Total iron positive cells and iron score index levels were calculated by enumerating the different grade of iron scored cells (Grade 0, 1, 2 and 3) using Perls’-DAB stained (see below) BAL cytospins.

**Mouse models of iron overload**

We utilised two models of iron overload to assess the effects of iron on asthma. We first used female \( Hfe^{-/-} \) and WT mice (36 weeks old) (2) on an AKR background strain that were fed a normal diet. Disruption of this gene results in deficiency in hepcidin production, leading to increased systemic iron levels (2-4). In addition, female BALB/c mice (6-8 weeks of age) were fed a diet of mouse chow that contains 2% carbonyl iron (19410mg Fe/Kg diet, Specialty Feeds, Western Australia) ad libitum for 8 weeks. This results in a similar level of iron load in the liver as \( Hfe^{-/-} \) mice. WT BALB/c mice were also maintained on control iron diet (~49 mg Fe/Kg diet) or low iron diet (~2.5mg Fe/Kg diet, Speciality Feeds, Western Australia) for 8 weeks as a comparison. All mice were housed at 22 ± 2°C temperature with humidity range of 30-70 under 12 hours dark/light cycling conditions.

**HDM-induced chronic experimental asthma**
WT AKR and Hfe\(^{-/-}\) female mice (~36 weeks old), and WT BALB/c female mice (8 weeks old) fed low iron, control and high iron diets were intranasally administered HDM extract (25μg, 50 μl PBS, Greer Laboratories, Lenoir, NC) or vehicle (PBS) 5 days per week for 6 weeks. After 6 weeks, liver and lung tissues were collected for further analysis, and AHR was measured.

**Perls’ and DAB-enhanced Perls’ stain**

The single lobed lungs from mice were perfused with saline, inflated and fixed with formalin, paraffin-embedded, and sectioned (4-6µm). Sections were deparaffinised with xylene and a graded series of ethanol. Deparaffinised mouse lung sections or BAL cell cytospins prepared from clinical and experimental samples were submerged in fresh 1% Potassium Ferrocyanide (AnalaR), pH 1 (Perls’ solution), for 30 min on a shaker. Each slide was washed briefly in distilled water, incubated in methanol containing 0.01M NaN\(_3\) (MERCK) and 0.3% H\(_2\)O\(_2\) for 1 h on a shaker. Slides were rinsed in 0.1M PBS (pH7.4) and iron staining was enhanced by 1 h of incubation with 0.025% 3, 3’-Diaminobenzidine-4HCl (DAB, MP Biomedical) and 0.005% H\(_2\)O\(_2\) in 0.1M PBS (pH 7.4) on a shaker. Slides were then washed in distilled water, dehydrated with a series of graded ethanol, cleared with xylene, and cover slipped using DEPEX mounting medium (BDH Chemical).

**Non-haem iron assay for the assessment of iron levels in BAL supernatants and tissue**

Non-haem iron content in BAL supernatants from severe or mild-moderate asthma patients or healthy controls, and in murine liver and lung tissues were measured as previously described (5). For the latter, briefly, ~50mg of wet tissues of liver or lung were homogenised in 1 ml of 0.9% NaCl solution on ice. Iron standard solutions ranging in concentration from 0 to 8μg/ml
were prepared from a stock solution of 5mM FeSO$_4$ (BDH Chemical). Then 100µl of iron standards or BAL supernatant or tissue homogenates were mixed with 50µL of 3.8M (12%) HCl and incubated at 85°C for 30 min. Then, 25µL of 50% trichloroacetic acid (Sigma-Aldrich, Australia) was added into each tube followed by incubated on ice for 10 min. After centrifugation (235 xg, room temperature, 20 min), 100 µl of supernatant was removed from each tube and added in triplicate to clear 96-well plates. Finally, 100µl of colour reagent (816µM bathophenanthroline disulfonic acid, 1.9M sodium acetate, 0.2% (v/v) thioglycolic acid; Sigma) was added to each well to develop colour and absorbance was measured at 560nm using a microplate reader (Synergy2, Millennium Science). After subtracting absorbance of blank samples, iron concentrations were calculated from the standard curve.

### Gene expression analysis by RT-qPCR

Total RNA was extracted from frozen mouse lung tissues using Trizol reagent (Invitrogen, Life Technologies, Australia) as described previously (6). Mouse total RNA (1µg) was reverse transcribed into cDNA using Bioscript (Bioline, Australia) and random hexamer primers (Invitrogen, Life Technologies, Australia). For human airway biopsy tissues, total RNA was isolated using QIAGEN RNeasy Mini kit for human airway biopsy tissue homogenates (Qiagen, Venlo, Netherlands, Cat# 990394) according to the manufacturer’s instructions. Human cDNA was collected using a reverse transcription kit (Applied Biosystems, USA). The level of mRNA transcripts for iron regulatory molecules and cytokines were measured by SYBR-green qPCR using Eppendorf RealPlex (Eppendorf, Germany) and relative expression was normalised to transcripts of $HPRT$ (mouse gene expression) or beta actin (human gene expression) (7-9). The formula used for calculating relative expression of each gene of interest was $2^{(Ct \text{ gene of interest} - Ct \text{ HPRT})}$ (10). Primer sequences are shown in Tables E1 and 2. Total mRNA from primary human ASM cells and lung fibroblast culture experiments was isolated using the
ISOLATE II RNA Mini Kit and transcribed into cDNA using the SensiFAST™ cDNA Synthesis Kit (Bioline, Alexandria, Australia), according to the manufacturer’s instructions. Assays were carried out in triplicate using a reaction mixture containing the Bioline SensiFAST Probe Hi-ROX Master Mix and TaqMan primer sets for \textit{TNF} (Hs01115665_m1) and the ubiquitously expressed ribosomal RNA (18S rRNA) as a housekeeping gene. qPCR was performed using the StepOnePlus detection system and data were collected and analysed by StepOne software (Applied Biosystems, Melbourne, Australia).

**Mouse BAL**

BAL collection, processing and cytospin preparations were performed as described previously (11). BAL cells cytospin slides were stained with May-Grunwald-Giemsa, differential immune cells were counted (≈175) using light microscopy at 40x magnification based on key morphological characteristics (12, 13).

**Lung tissue eosinophil and airway mucus-secreting cell numbers**

Lung sections were deparaffinised and stained with chrome salt fixation (for eosinophils) or periodic acid–Schiff (for mucus-secreting cells). Numbers of eosinophils and PAS positive cells (i.e. mucus secreting cells) were counted per 100μm around the airways at 100x magnification as previously described (12, 13).

**Small airway remodelling**

Airway remodelling in terms of collagen thickness around the small airways was evaluated in at least 6 small airway images (40x magnification) from Sirius Red and Fast Green-stained (Sigma Aldrich, USA) mouse lung sections using ImageJ (version 1.47, Media Cybernetics, Rockville, MD, USA) as previously described (11).
AHR

AHR in terms of central airway resistance (Rn) in response to nebulised methacholine (MCh) was measured using FlexiVent apparatus (FX1 System; SCIREQ, Montreal, Canada). Briefly, mice were anaesthetised with a mixture of ketamine (100mg/kg, Parnell) and xylazine (10mg/kg, Troy Laboratories, Smithfield, Australia). Following tracheostomy, cannulae were inserted into their tracheas and ligated (7, 12-14). Rn (tidal volume of 8mL/kg at a respiratory rate of 450 breaths/min) was measured in response to increasing doses of nebulised MCh (up to 30mg/kg; Sigma-Aldrich, Sydney, Australia) (14).

IL6, IL8 and transferrin detection. Levels of IL-6 and IL-8 in cell-free supernatants were measured by sandwich ELISA, using commercial antibody kits according to the manufacturer’s instructions (R&D Systems, MN). The detection limit of both assays was 15.6 pg/ml. Levels of transferrin in BAL supernatants were measured using commercial ELISA kit according to the manufacturer’s instructions (Abcam: ab157724).

Flow cytometric analysis of macrophage populations in murine lung tissue.

Flow cytometry was performed on murine whole lung single cell suspensions to determine the number and activation of macrophage subsets (15). Lung tissue was processed into single cell suspensions via enzymatic digestion with collagenase D (2mg/mL, Roche, Sydney, Australia), DNase I (400U/mL, Roche) and a gentleMACSTM Dissociator (Miltenyi Biotec). Total lungs cells were collected, and red blood cells lysed (155mM NH4Cl, 12mM NaHCO3, 0.1mM ethylenediaminetetraacetic acid [EDTA], pH 7.35, 5mins, 4°C). Total cell counts were performed using a haemocytometer under a light microscope (20x magnification) and trypan blue (Sigma-Aldrich) exclusion. Total cells stained with fluorescently conjugated antibodies
specific for CD45, F4/80, CD11c, CD11b, Ly6C, SiglecF and TFR1 (Table E3) (BD Biosciences, San Diego, USA; Biolegend, San Diego, USA). Live cell discrimination was assessed with Zombie yellow fixable viability dye (Biolegend). Cells were then analysed using a LSR Fortessa X-20 (BD Biosciences) and FACSDiva software (BD Biosciences). After exclusion of cell debris, doublets and dead cells, macrophage subsets were determined based on antigen expression (Table E4).

**Isolation of macrophages from whole lung tissue.** Lungs were processed into single cell suspensions and stained with fluorochrome-conjugated antibodies as above. Tfr1+ macrophages were isolated by fluorescence-activated cell sorting using an ARIA III (BD Biosciences) into PBS with 5% FCS.

**RNA extraction from isolated macrophages and reverse transcription (RT).**

Total RNA was extracted from sorted Tfr1+ macrophages using miRNeasy mini kit (Qiagen, Chadstone, Australia) as per manufacturer’s instructions. Sorted cells were collected into Qiazol® (750µL) and stored at -80°C until RNA extraction. Upon thawing of cells, chloroform (140 µL) was added and vortexed prior to phase separation by centrifugation (15min, 4°C, 12,000xg). The aqueous phase was collected before automated RNA extraction using Qiacube apparatus (Qiagen). This automated protocol supplemented samples with 100% molecular grade ethanol prior to centrifugation. Samples were transferred to spin columns and washed with RWT buffer. RPE buffer was added to columns prior to further centrifugation. Purified RNA was eluted using RNAse-free water. RNA purity and concentration were determined using a NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific, North Ryde, Australia). The 260/230nm and 260/280nm absorption ratios accepted as pure RNA was >1.90, and >2.00, respectively. RNA from isolated macrophages was reverse transcribed to cDNA.
using the miScript II RT kit (Qiagen) as per manufacturer’s instructions. Samples were supplemented with miScript HiFlex buffer (4µl), 10x miScript Nucleics mix (2µl) and miScript reverse transcriptase mix (2µl). Reverse transcription was achieved using a Bio-Rad T100 Thermal Cycler (60min, 37°C; 5min, 95°C). Samples were then stored at -20°C until quantification by qPCR.

**ASM cell and lung fibroblasts culture.** Primary human ASM cells and lung fibroblasts were isolated from the parenchyma of lungs from patients undergoing lung transplantation as previously described (16). Patient demographics are described in Table E6. Cells were seeded in 12 or 96 well plates at 4.5×10^4 cells/mL in DMEM with 5% fetal bovine serum and 1% antibiotic-antimycotic, and cultured to near confluence (72h, 37°C, 5% CO₂). Cells were serum starved in DMEM with 0.1% bovine serum albumin for 24h prior to stimulation. Cells were stimulated with a range of ferric ammonium citrate (FAC) concentrations for 48h, with additions replenished at 24h. Cell free supernatants or total RNA lysates were collected at 48h and stored at -20°C for analysis. All experiments were carried out using fibroblasts between passage 2 and 4.

**Primary bronchial airway epithelial cells (pBECs) cultured at the air-liquid interface (ALI) (17).** Human pBECs were obtained from healthy controls, and patients with severe asthma. pBECs were raised and maintained in placental collagen-coated T75 tissue culture flasks (Interpath, Australia) with Bronchial Epithelial Cell Growth Medium (BEGM™, Lonza, USA), supplemented with BEGM™ SingleQuots™ supplements and Growth Factors (BEGM™ BulletKit™, Lonza), penicillin/streptomycin (Life Technologies, USA) and amphotericin B (Sigma, USA). Cell monolayers at 70%-80% confluency were detached with 1:10 trypsin-ethylenediaminetetraacetic acid/Dulbecco’s phosphate buffered saline (1:10
trypsin-EDTA/D-PBS, 4mL). Trypsin enzyme activity was neutralised with foetal bovine
serum (FBS) and cells were resuspended in ALI initial medium. Detached cells were then
enumerated and seeded at 2x10^5 cells/500μL initial media onto the apical compartment of a
12-well plate (Corning, USA) containing a 12mm polyester membrane transwell (0.4μm pore
size, Sigma). ALI initial media was also added to the basal compartment (1.5mL/well) and
refreshed (1.5mL/well) 24h after seeding. At 72h post-seeding, all apical media was removed
and basal media replaced with ALI final medium (1.5mL/well). This timepoint was demarcated
as “day 0” of ALI culture and the beginning of the experimental period. Basolateral media was
replaced every two days with 1.5mL fresh ALI final medium. Apical surfaces of the ALI
cultures were washed with sterile 1xD-PBS (500uL/well) weekly, and trans-epithelial electrical
resistance measured (Epithelial Volt/ohmmeter 2 [EVOM2], Coherent Scientific) to track
monolayer formation. This weekly apical wash also served to remove any mucus build-up from
the cultures. Patient cells were grown at ALI in culture conditions (37°C, 5% CO₂) for 28 days
to ensure maximal differentiation. Following sufficient differentiation of the cells basal media
was replaced with ALI minimal media (1.5 mL/well) and incubated overnight (37°C, 5% CO₂).
Apical compartments of each well were then supplemented with minimal media and 1xD-PBS
(500uL) and basal minimal media was replaced (1.5mL) prior to the second overnight
incubation (37°C, 5% CO₂). At the end of the protocol, apical and basal media was removed
and stored at -80°C for further analysis. Cells from the apical ALI membrane insert were also
harvested and stored in Qiazol® lysis reagent (700uL, Qiagen, -80°C) for further processing.

Statistics

Comparisons between two groups were performed using a non-parametric Mann-Whitney test.
Comparisons between multiple groups were performed using Kruskal-Wallis one-way analysis
of variance (ANOVA) with uncorrected Dunn’s post-hoc test. AHR data were analysed using
two-way repeated measures ANOVA with Bonferroni post-hoc test. Correlation analyses were performed using Spearman rank correlation. All statistical analysis was performed using GraphPad Prism V.7 Software (San Diego, California, USA).

Supplementary results

HDM-induced experimental asthma

Intranasal HDM-treatment increases the number of immune cells (macrophages, neutrophils, eosinophils) in BAL, airway tissue eosinophil numbers, mucus secreting cell numbers, and collagen deposition in airway tissue and this is associated with increased airway hyper-responsiveness (AHR) (Figure E2 A-F).

Supplementary discussion

We show a significant increase in iron positive BAL cells in subjects with severe and mild-moderate asthma compared to healthy controls. Increased numbers of iron-laden cells have been reported in patients with COPD (18), IPF (19) and cigarette smokers (20). The increased iron in the lung of cigarette smokers may not be dyshomeostasis, but actual loading of lungs with additional iron on inhalation. However, these findings do suggest that increased numbers of iron laden cells in the airways is a key feature of several lung diseases. Our data is also consistent, with a recent case report where haemosiderin-laden macrophages were identified in BAL from an 8-year old child with recurrent iron-deficiency anaemia (IDA) and allergic asthma and later diagnosed with idiopathic pulmonary haemosiderosis (IPH) (21). However,
since this study is based on a single patient it is unclear whether IDA and/or macrophage haemosiderin are associated with allergic asthma or IPH.

To protect from the potentially harmful effects of excess free iron, iron regulatory systems must be tightly regulated in the body. Although little is known about the iron metabolism in the lung, as with other organs, iron homeostasis in the lung is maintained by a range of iron regulatory molecules, including iron uptake (transferrin receptors, TFR1, TFR2); divalent metal transporter 1 (DMT1); zinc transporter protein 14 (ZIP14); natural resistance-associated macrophage protein 1 (NRAMP1) and lactoferrin receptor (LFR); transport (Transferrin, TF), storage (ferritin heavy and light chain, FTH, FTL) and export (ferroportin, FPN) from cells. Iron-responsive proteins (IRPs) control the expression of these genes through binding with the 5' or 3' untranslated regions of these genes mRNA (22).

We show that NRAMP1 expression is higher in the airways of mild-moderate asthma patients and tends to further increase in severe asthma compared to healthy controls (Figure 3C). NRAMP1 has been reported to affect IgE responses, the development of Th2 cell responses and mast cell degranulation in ovalbumin-induced allergic asthma in mice (23). We also show increased TFR2 in the airways of severe asthma patients (Figure 3A). TFR2 acts as an iron sensor of transferrin-bound iron (Fe-TF) that stimulates hepcidin production (24). In addition, ZIP14 levels have been shown to increase in airway cells in iron overload and decrease in iron deficiency in mice (25). We show increased FTH and IRP1 expression in airways of mild-moderate but not severe asthma patients (Figure 3D, F). Furthermore, FTL expression reduced (p=0.06) in the airways of severe compared to mild-moderate asthma patients (Figure 3E). Another study suggested that FTL has anti-inflammatory effects, which agree with our findings (26). In addition, we find that the only known iron exporter, FPN expression is not altered in asthma (Figure 3H). All these data provide strong evidence that
there is an environment of increased iron sequestration into cells in asthmatic airways that leads to increased cellular but reduced extracellular iron levels in BAL in asthma.

To explore the relationship between iron and asthma, we performed a series of studies to determine the effects of LID on key disease features. Decreasing systemic iron levels using a LID had no effect on lung iron levels but increased AHR in the absence of HDM-induced experimental asthma. However, we also show that a LID reduces iron accumulation in HDM-induced experimental asthma and protects against some of the key features of disease. These findings highlight the complexity and importance of systemic:local iron regulatory interactions in the pathogenesis of asthma, and also demonstrates that both low and high systemic iron may promote/increase the severity of key disease features in different contexts, which is consistent with the controversy in the literature (27-32).

Whilst our findings demonstrate that increased iron accumulation in cells and tissues in the airways and lung is linked to key features of asthma and plays a role in the worsening of lung function and disease severity, they do not elucidate the underlying mechanisms involved in iron-mediated effects. A large body of evidence suggests that iron-induced oxidative stress may play a key role (24). Iron accumulation has been suggested to induce oxidative stress and contribute to the pathogenesis of Alzheimer’s disease, atherosclerosis and Parkinson’s disease (33), and there is a clear involvement of oxidative stress in asthma (34, 35). Increased production of ROS and reactive nitrogen species (RNS) and reduced or inactivated antioxidant responses occur in patients with bronchial asthma (36-40). Lipid peroxidation in plasma and exhaled breath condensate (EBC) is inversely correlated with airflow obstruction in asthma (41). In addition, total antioxidant capacity in plasma and sputum, and SOD levels in plasma and airway epithelial cells (AEC) have been reported to be positively associated with airflow obstruction in asthmatics (41). Chronic inflammation can generate ROS (42), and overproduction of ROS/RNS reportedly leads to airway inflammation and remodelling, mucus
overproduction, tissue injury and lung function decline in clinical and experimental asthma studies (43, 44). Notably, a significant increase in iron and MDA levels in plasma have been shown in asthmatics, and there is a positive correlation between MDA and iron levels (32), suggesting that increased systemic iron may promote asthma. Furthermore, increased levels of oxidative stress (increased MDA, catalase, SOD, GPX and nitrotyrosine levels) and inflammatory responses (increased HIF1α, NF-κB and TNFα levels) with increased iron accumulation in the lung have been shown in rats treated with low molecular weight iron dextran (45). Based on this evidence, increased iron may drive disease through increased oxidative stress in tissues that drives many of the key features of disease.

Ferroptosis, a process of iron-dependent programmed cell death, has recently been suggested to be a key molecular mechanisms implicated in kidney, brain, liver, heart and lung pathology (46-51). Recently, Wenzel et al., uncovered evidence for phosphatidylethanolamine-binding protein 1 (PEBP1)-dependent regulatory mechanisms of ferroptotic death in AEC in asthma (52). Since we show that experimental asthma results in increased iron accumulation in lung cells and tissues as well as evidence for increased iron sequestration in clinical airway samples, it is possible that increased iron accumulation-mediated ferroptotic cell death may contribute to disease pathogenesis. However, further studies are required to explore mechanisms of the association between iron and ferroptosis in asthma pathogenesis and to determine the Fe^{2+/3+} status and localisation within airway cells.

In the lung, iron can also be derived from non-dietary sources e.g smoking, pollution or geogenic iron. Increased iron accumulation in the lung as a result of these exogenous exposures may also contribute to lung pathology. Indeed, Indeed, a recent study has shown that increased concentrations of iron in particulate matter result in lung impairment 7 days-post intranasal exposure in mice (53). It is also important to note that infections are associated with the development of asthma phenotypes and that humans and mice with asthma or allergic
airway disease have altered microbiomes and predispose to respiratory infections that increase
the severity or exacerbate their disease (24). Excess iron can also increase susceptibility to
respiratory infections (24), which may modify the immune system and promote disease
pathogenesis.

Due to the limited availability of appropriate airway tissue samples, and the prospective
nature of our analyses, we needed to draw bronchoscopy samples from two different cohorts.
We note that there was no significant difference in asthma control questionnaire (ACQ) and
BAL cellular profiles in the cohorts that we used for BAL non-haem iron studies. Our findings
from these two different cohorts highlight that iron levels and regulation are altered in asthma.

References

1. Vlahos R, Wark PA, Anderson GP, Bozinovski S. Glucocorticosteroids differentially

DA, Prass CE, Schatzman RC, O'Neill R, Britton RS, Bacon BR, Sly WS. HFE gene
knockout produces mouse model of hereditary hemochromatosis. *Proc Natl Acad Sci

CA. Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice. *Blood*
2010; 115: 3374-3381.

4. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor


Supplementary figure legends

Figure E1. Iron diets and HDM-induced experimental asthma protocol.

Figure E2. House dust mite (HDM)-induced experimental asthma. Six-8-week-old wild-type (WT) BALB/c mice were intranasally administered HDM antigen for 5 days per week for 6 weeks and then major features of experimental asthma were assessed. Total and differential immune cells were enumerated in bronchoalveolar lavage and cytospin slides stained with May-Grunwald-Giemsa (A). Tissue eosinophil numbers were assessed in chrome salt fixation-stained lung sections (B). Mucus secreting cells (MSCs) were enumerated around inflamed airways in PAS-stained lung sections (C, D). Area of collagen deposition surrounding the basement membrane of small airways was quantified in Sirius red-stained lung tissue sections, in 6-8 airways/mouse, using ImageJ (E). Airway hyper-responsiveness (AHR) was measured in terms of central airway resistance (Rn) to inhaled increasing concentrations of nebulised methacholine (Mch) using Flexivent apparatus (F). Scale bar: 50 μm. Data are presented as mean ± SEM (n=6-8), pooled from two repeat experiments. **p<0.01; ***p<0.001; ****p<0.0001 compared to PBS controls.

Figure E3. Bronchoalveolar lavage (BAL) cell profiles in house dust mite (HDM)-induced experimental asthma in WT and Hfe<sup>−/−</sup> AKR mice. HDM was administered to ~36 week-old wild-type (WT) and Hfe<sup>−/−</sup> AKR mice for 5 days per week for 6 weeks and then differential immune cells were enumerated in BAL and cytospin slides stained with May-Grunwald-Giemsa. Data are presented as mean ± SEM (n=6-10), pooled from 2 repeat experiments. *p<0.05; **p<0.01; ***p<0.001.

Supplementary tables
Table E1. Custom-designed primers for human mRNA used in qPCR analyses.

Table E2. Custom-designed primers for mouse mRNA used in qPCR analyses.

Table E3. Antibodies used for flow cytometry

Table E4. Antigenic definitions for macrophage analyses conducted by flow cytometry

Table E5. Human bronchial airway epithelial cells (pBECs) donor characteristics

Table E6. Human airway smooth muscle cell and lung fibroblast donor characteristics

Figure E1.
Figure E2.

Figure E3.
### Table E1.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer sequence (5' → 3')</th>
<th>Target gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta Actin Forward</td>
<td>CTGGCAACACACCCTTCTTA</td>
<td>Beta Actin</td>
</tr>
<tr>
<td>Beta Actin Reverse</td>
<td>GGTGTGAACTGTAGGCT</td>
<td>Beta Actin</td>
</tr>
<tr>
<td>DMT1 Forward</td>
<td>AGGCCAGACTTTGTTGGATTTGAA</td>
<td>DMT1</td>
</tr>
<tr>
<td>DMT1 Reverse</td>
<td>AGTACATATTGATGGAACAG</td>
<td>DMT1</td>
</tr>
<tr>
<td>FPN Forward</td>
<td>CTTGCCATAATCTCTGTC</td>
<td>FPN</td>
</tr>
<tr>
<td>FPN Reverse</td>
<td>CATTATTAAATGCCTTTTCA</td>
<td>FPN</td>
</tr>
<tr>
<td>HMP Forward</td>
<td>CTGTTTTCCCACACAGACG</td>
<td>HEPC1</td>
</tr>
<tr>
<td>HMP Reverse</td>
<td>CAGCACATCCACCACCTTGA</td>
<td>HEPC1</td>
</tr>
<tr>
<td>TFR1 Forward</td>
<td>AGGAACCGAGTCTCCAGTGA</td>
<td>TFR1</td>
</tr>
<tr>
<td>TFR1 Reverse</td>
<td>ATCAACTATGATACCGAGT</td>
<td>TFR1</td>
</tr>
<tr>
<td>TFR2 Forward</td>
<td>GAGTTGCTAGAAGGCTACCTCA</td>
<td>TFR2</td>
</tr>
<tr>
<td>TFR2 Reverse</td>
<td>GGTCTTGGCATGAACCTTGCA</td>
<td>TFR2</td>
</tr>
<tr>
<td>FTL Forward</td>
<td>CCCATGACCTCCAGATTCTG</td>
<td>Ft L</td>
</tr>
<tr>
<td>FTL Reverse</td>
<td>CCAAGAGCAGACATACGCTC</td>
<td>Ft L</td>
</tr>
<tr>
<td>FTH Forward</td>
<td>CACGAACTACACCAGGACT</td>
<td>Ft H</td>
</tr>
<tr>
<td>FTH Reverse</td>
<td>CCATTATGCCCAAAGGCTACTGA</td>
<td>Ft H</td>
</tr>
<tr>
<td>ZIP14 Forward</td>
<td>GGTATTGAGAAGCCACCTCACGT</td>
<td>ZIP14</td>
</tr>
<tr>
<td>ZIP14 Reverse</td>
<td>AGGTGCTGTCCTGCAAGCTC</td>
<td>ZIP14</td>
</tr>
<tr>
<td>NRAMP1 Forward</td>
<td>TTCTGCCTCAAAGGAGACG</td>
<td>NRAMP1</td>
</tr>
<tr>
<td>NRAMP1 Reverse</td>
<td>GTTGCGAGCAGCGAACAGAGAAG</td>
<td>NRAMP1</td>
</tr>
<tr>
<td>IRP1 Forward</td>
<td>CGTGCACTCGAGGAAACACAC</td>
<td>IRP1</td>
</tr>
<tr>
<td>IRP1 Reverse</td>
<td>TCGAAAATGGTAAGCGCCCA</td>
<td>IRP1</td>
</tr>
</tbody>
</table>

### Table E2.

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer sequence (5' → 3')</th>
<th>Target gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hprt Forward</td>
<td>AGGCCAGACTTTGTTGAGTTGAA</td>
<td>Hprt</td>
</tr>
<tr>
<td>Hprt Reverse</td>
<td>CAACCTGGCTGCTACCTGAGTTT</td>
<td>Hprt</td>
</tr>
<tr>
<td>Il13 Forward</td>
<td>TGCTTGCCCTGTTGCTCTCT</td>
<td>Il13</td>
</tr>
<tr>
<td>Il13 Reverse</td>
<td>GGAGAGTCCTGGTGCTG</td>
<td>Il13</td>
</tr>
<tr>
<td>Tfr1 Forward</td>
<td>CCCATGACGTTGAACTGACCTGA</td>
<td>Tfr1</td>
</tr>
<tr>
<td>Tfr1 Reverse</td>
<td>GTAGTCTCCAGACGAGCAGAT</td>
<td>Tfr1</td>
</tr>
<tr>
<td>Il10 Forward</td>
<td>AGGCCGCTGTCATCAGATTCTC</td>
<td>Il10</td>
</tr>
<tr>
<td>Il10 Reverse</td>
<td>ATGCCGTGAGCATGACCTTTG</td>
<td>Il10</td>
</tr>
<tr>
<td>Ifng Forward</td>
<td>CTTGAAGCGCGCAGCAGAGAAG</td>
<td>Ifng</td>
</tr>
<tr>
<td>Ifng Reverse</td>
<td>TGGATTGAGCAGGCTGAGCTG</td>
<td>Ifng</td>
</tr>
<tr>
<td>Tgfb1 Forward</td>
<td>CCCGAAGCGGACTGATGCTA</td>
<td>Tgfb1</td>
</tr>
<tr>
<td>Tgfb1 Reverse</td>
<td>GGTAAAGCGAGAGTATTGCTAT</td>
<td>Tgfb1</td>
</tr>
</tbody>
</table>

### Table E3. Antibodies used for flow cytometric staining

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Fluorophore</th>
<th>Clone</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD45</td>
<td>PerCP</td>
<td>30F-11</td>
<td>Biolegend</td>
</tr>
<tr>
<td>CD11c</td>
<td>Brilliant violet (BV)421</td>
<td>N418</td>
<td>Biolegend</td>
</tr>
<tr>
<td>CD11b</td>
<td>Alexa Fluor (AF)700</td>
<td>M1/70</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td>SiglecF</td>
<td>Phycoerythrin (PE)</td>
<td>E50-2440</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td>F4/80</td>
<td>BV711</td>
<td>T45-2342</td>
<td>Biolegend</td>
</tr>
<tr>
<td>Ly6C</td>
<td>PE-Cy7</td>
<td>A1-21</td>
<td>BD Biosciences</td>
</tr>
<tr>
<td>TFR1</td>
<td>APC</td>
<td>R17217</td>
<td>Biolegend</td>
</tr>
</tbody>
</table>
Table E4. Antigen definitions for macrophage flow cytometric staining

<table>
<thead>
<tr>
<th>Granulocyte type</th>
<th>Antigen definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total macrophages</td>
<td>CD45⁺, F480⁺, CD11c&lt;sub&gt;hi&lt;/sub&gt;⁻&lt;sup&gt;c&lt;/sup&gt;, SiglecF&lt;sub&gt;hi&lt;/sub&gt;⁻&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Alveolar Macrophage</td>
<td>CD45⁺, F4/80⁺, CD11b⁻, CD11c&lt;sup&gt;hi&lt;/sup&gt; SiglecF&lt;sup&gt;hi&lt;/sup&gt;</td>
</tr>
<tr>
<td>Interstitial Macrophage</td>
<td>CD45⁺, F4/80⁺, CD11b⁻, CD11c&lt;sup&gt;hi&lt;/sup&gt;, SiglecF⁻, Ly6C⁻</td>
</tr>
<tr>
<td>Monocytes</td>
<td>CD45⁺, F4/80⁺, CD11b⁺, CD11c⁺, SiglecF⁻, Ly6C⁺</td>
</tr>
</tbody>
</table>

Table E5.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Healthy</th>
<th>Asthmatics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects, n</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Age, yr</td>
<td>62.63 ± 5.873</td>
<td>56.86 ± 5.595</td>
</tr>
<tr>
<td>Sex, M/F</td>
<td>2/6</td>
<td>2/5</td>
</tr>
<tr>
<td>FEV1% predicted</td>
<td>84.25 ± 5.230</td>
<td>78.43 ± 6.931</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>0.747 ± 0.030</td>
<td>0.723 ± 0.021</td>
</tr>
<tr>
<td>ACQ</td>
<td>-</td>
<td>2.400 ± 0.623</td>
</tr>
<tr>
<td>Total cells (x10⁶/mL BAL)</td>
<td>0.667 ± 0.391</td>
<td>3.717 ± 3.345</td>
</tr>
<tr>
<td>Macrophages (%)</td>
<td>47.75 ± 13.93</td>
<td>41.67 ± 13.48</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>22.75 ± 11.00</td>
<td>44.29 ± 14.64</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>0.850 ± 0.217</td>
<td>1.833 ± 0.363</td>
</tr>
<tr>
<td>ICS, yes/no</td>
<td>NA</td>
<td>7/0</td>
</tr>
<tr>
<td>ICS dose&lt;sup&gt;5&lt;/sup&gt;</td>
<td>NA</td>
<td>717.10 ± 114.7</td>
</tr>
<tr>
<td>LABA, yes/no</td>
<td>NA</td>
<td>6/1</td>
</tr>
<tr>
<td>LAMA, yes/no</td>
<td>NA</td>
<td>2/5</td>
</tr>
<tr>
<td>SABA, yes/no</td>
<td>NA</td>
<td>3/4</td>
</tr>
<tr>
<td>OCS, yes/no</td>
<td>NA</td>
<td>0/7</td>
</tr>
</tbody>
</table>

Table E6.

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Disease</th>
<th>Gender</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pulmonary fibrosis</td>
<td>F</td>
<td>54</td>
</tr>
<tr>
<td>2</td>
<td>Pulmonary fibrosis</td>
<td>M</td>
<td>64</td>
</tr>
<tr>
<td>3</td>
<td>Bronchiectasis</td>
<td>M</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>IPF</td>
<td>M</td>
<td>65</td>
</tr>
<tr>
<td>5</td>
<td>Telomere-associated pulmonary fibrosis</td>
<td>F</td>
<td>45</td>
</tr>
<tr>
<td>6</td>
<td>COPD</td>
<td>M</td>
<td>61</td>
</tr>
<tr>
<td>7</td>
<td>NSCC</td>
<td>F</td>
<td>60</td>
</tr>
<tr>
<td>8</td>
<td>Pulmonary fibrosis</td>
<td>M</td>
<td>68</td>
</tr>
<tr>
<td>9</td>
<td>Emphysema</td>
<td>F</td>
<td>57</td>
</tr>
<tr>
<td>10</td>
<td>Emphysema</td>
<td>M</td>
<td>65</td>
</tr>
<tr>
<td>11</td>
<td>bronchiectasis</td>
<td>F</td>
<td>38</td>
</tr>
<tr>
<td>12</td>
<td>BOS (re-do)</td>
<td>F</td>
<td>28</td>
</tr>
</tbody>
</table>

M/F, male/female; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ACQ, asthma control questionnaire; BAL, bronchoalveolar lavage; NA, not applicable; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; OCS, oral corticosteroids; yr, year. <sup>5</sup>Equivalent to Fluticasone μg/day. Data are shown as mean ± SEM.
<table>
<thead>
<tr>
<th></th>
<th>Diagnosis</th>
<th>Gender</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Emphysema</td>
<td>M</td>
<td>60</td>
</tr>
<tr>
<td>14</td>
<td>Pulmonary fibrosis</td>
<td>M</td>
<td>53</td>
</tr>
</tbody>
</table>

M, male; F, female.